entertainment -WSS

entertainment

author：comprehensive 2025-10-02 22:27:46 - browse：628

Christopher Viehbacher on stage at the 2023 STAT Summit. — Biogen CEO Christopher Viehbacher STAT

Two years after a big scientific swing nearly pushed Biogen to the brink, CEO Christopher Viehbacher is embarking on a corporate rethink, one that balances Biogen’s characteristic risky bets with a frank commitment to pragmatism.

Speaking at the STAT Summit in Boston on Thursday, Viehbacher said his Biogen predecessors fell off track through a few unsound investments and an all-or-nothing bet on Aduhelm, the Alzheimer’s disease treatment that became a pharmaceutical cautionary tale. Viehbacher, one year into his tenure at the storied company, said Biogen’s future will rely on taking a more disciplined approach to risk.

“There’s a huge amount of pride inside the company that we go after problems other people don’t,” Viehbacher said, “but at the end of the day you also have to get medicines through the pipeline to benefit patients, and that’s why we’re expanding the aperture of what we’re doing in R&D.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Anavex keeps shifting the goalposts in its clinical trials

WSS

The best solution to the drug shortages problem

Drastic changes should bring profitability, startup health insurers say

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

The Pandemic Treaty must support building strong health systems

Woman returns to dialysis after doctors remove transplanted pig kidney

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Wikipedia

entertainment

entertainment

The cancer drug shortage isn’t new — and neither are the solutions

Naloxone nonprofit donates 200,000 doses after FDA approval

23andMe had bad news about my health. I wish a person had delivered it

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Virginia high school admissions case could be legal follow

The best solution to the drug shortages problem

Medicare details structure of new drug price negotiation program

FDA's Pazdur wants cancer trials to range beyond China alone

Medicare details structure of new drug price negotiation program

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

hotspot

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

South Korea throws huge K

BMI, flaws aside, is found to be useful estimate of body fat in youth

ASCO: Palliative care found as helpful given virtually as in person

ASCO: AstraZeneca says CAR

NIH trials fail to test meaningful long Covid therapies, experts say

focus

entertainment

Wikipedia

hotspot